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Abstract: Application of chondroreparative gene vectors in cartilage defects is a powerful approach
to directly stimulate the regenerative activities of bone-marrow-derived mesenchymal stem cells
(MSCs) that repopulate such lesions. Here, we investigated the ability of combined recombinant
adeno-associated virus (rAAV) vector-mediated delivery of the potent transforming growth factor
beta (TGF-β) and insulin-like growth factor I (IGF-I) to enhance the processes of chondrogenic
differentiation in human MSCs (hMSCs) relative to individual candidate treatments and to reporter
(lacZ) gene condition. The rAAV-hTGF-β and rAAV-hIGF-I vectors were simultaneously provided
to hMSC aggregate cultures (TGF-β/IGF-I condition) in chondrogenic medium over time (21 days)
versus TGF-β/lacZ, IGF-I/lacZ, and lacZ treatments at equivalent vector doses. The cultures were
then processed to monitor transgene (co)-overexpression, the levels of biological activities in
the cells (cell proliferation, matrix synthesis), and the development of a chondrogenic versus
osteogenic/hypertrophic phenotype. Effective, durable co-overexpression of TGF-β with IGF-I
via rAAV enhanced the proliferative, anabolic, and chondrogenic activities in hMSCs versus lacZ
treatment and reached levels that were higher than those achieved upon single candidate gene
transfer, while osteogenic/hypertrophic differentiation was delayed over the period of time evaluated.
These findings demonstrate the potential of manipulating multiple therapeutic rAAV vectors as a tool
to directly target bone-marrow-derived MSCs in sites of focal cartilage defects and to locally enhance
the endogenous processes of cartilage repair.
Keywords: cartilage repair; MSCs; rAAV vectors; TGF-β; IGF-I
1. Introduction
Articular cartilage lesions are prevalent clinical issues that impede the whole musculoskeletal
system and for which there is no definitive cure to date [1,2]. The articular cartilage, covering the
articular surface in the joints and forming an osteochondral unit in conjunction with the underlying
subchondral bone, allows for joint stability, elasticity of compression, and shock absorption. Adult
hyaline cartilage is an aneural, avascular tissue that uniquely consists of articular chondrocytes (5% of
the total tissue volume) embedded in a tight extracellular matrix essentially composed of proteoglycans
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and type-II collagen. In absence of vascularization, cartilage defects resulting from trauma or in
osteoarthritis (OA) do not have the ability to reliably restore their full, original architecture with
mechanical competence [1–4]. Even following surgical interventions based on bone-marrow-stimulating
techniques that allow to give access to bone-marrow-derived chondroregenerative progenitor cells
in sites of injury (microfracturing, abrasion athroplasty, pridie drilling), the resulting repair tissue is
chiefly made of fibrocartilage with type-I collagen as the main component and unable to withstand
mechanical loads [1–7].
Cartilage gene therapy that aims at activating the intrinsic chondroreparative activities of
bone-marrow-derived mesenchymal stem cells (MSCs) [8–10] may be envisaged by directly providing
therapeutic gene vehicles in sites of cartilage injury [11,12] especially using clinically relevant
recombinant adeno-associated virus (rAAV) vectors [13] that support the safe, effective, and durable
transduction of these cells (up to 100% efficiencies for at least 3 weeks) without alteration of their
chondrogenic potential [14–20]. Such a strategy has been reported using a number of therapeutic
(chondrogenic) candidates such as the transforming growth factor beta (TGF-β) [14,18], basic fibroblast
growth factor (FGF-2) [16], insulin-like growth factor I (IGF-I) [19], and the sex-determining region
Y-type high-mobility group box 9 transcription factor (SOX9) alone [17] or combined with TGF-β [20],
thus promoting the chondrogenic differentiation of the cells only to a certain extent and showing the
need to explore new setups and combinations that might be more valuable than single treatments [12,21].
Here, we therefore investigated the feasibility of co-overexpressing the pleiotropic and highly
chondrogenic TGF-β and IGF-I genes in hMSCs via rAAV-mediated gene transfer in order to stimulate
the reparative activities in these cells in vitro based on our previous findings showing the efficacy of
each of the therapeutic constructs in hMSCs independently [18,19]. Our results indicate that successful,
prolonged concomitant overexpression of TGF-β with IGF-I via rAAV led to enhanced proliferative,
anabolic, and chondrogenic activities in hMSCs aggregate cultures relative to independent gene
application (TGF-β with lacZ or IGF-I with lacZ) and control (reporter lacZ) treatment while restraining
undesirable osteogenic and hypertrophic differentiation. These data provide a basis to locally treat
and improve cartilage repair by directly co-delivering multiple therapeutic rAAV vectors in sites of
cartilage injury.
2. Results
2.1. Successful rAAV-Mediated TGF-β and IGF-I Co-Overexpression in hMSC Aggregates
hMSC aggregates were first transduced over time with rAAV according to the study design
(Figure 1) in order to evaluate the ability of the vectors to promote the co-overexpression of the
candidate TGF-β and IGF-I genes (TGF-β/IGF-I) relative to independent gene application (TGF-β/lacZ
or IGF-I/lacZ) and control (lacZ) treatment. Successful, durable rAAV-mediated expression of the TGF-β
and IGF-I transgenes was achieved in the specific conditions examined, especially in the TGF-β/IGF-I
aggregates (Tables 1 and 2 and Figure 2).
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Figure 1. Study design. Human bone-marrow-derived mesenchymal stem cells (MSCs) were 
prepared in high-density aggregate cultures (2 × 105 cells/aggregate) and placed in defined 
chondrogenic medium overnight prior to direct transduction with the recombinant adeno-associated 
virus (rAAV) vectors (TGF-β/IGF-I, TGF-β/lacZ, IGF-I/lacZ: 40 µL each vector/aggregate; lacZ: 80 µL 
vector/aggregate). rAAV-transduced aggregates were maintained in the defined chondrogenic 
medium for 21 days and analyzed to detect transgene expression and for biochemical analyses, 
immunohistochemistry and histology, and real-time RT-PCR analyses. 
Figure 1. Study design. Human bone-marrow-derived mesenchymal stem cells (MSCs) were prepared
in high-density aggregate cultures (2× 105 cells/aggregate) and placed in defined chondrogenic medium
overnight prior to direct transduction with the recombinant adeno-associated virus (rAAV) vectors
(TGF-β/IGF-I, TGF-β/lacZ, IGF-I/lacZ: 40 µL each vector/aggregate; lacZ: 80 µL vector/aggregate).
rAAV-transduced aggregates were maintained in the defined chondrogenic medium for 21 days and
analyzed to detect transgene expression and for biochemical analyses, immunohistochemistry and
histology, and real-time RT-PCR analyses.
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Figure 2. Detection of transgene (TGF-β, IGF-I) overexpression in rAAV-transduced hMSC 
aggregates. Aggregates were co-transduced with rAAV TGF-β/IGF-I, TGF-β/lacZ, IGF-I/lacZ or 
transduced with rAAV lacZ as described in Figure 1 and in the Materials and Methods. Samples were 
processed after 21 days to detect the expression of TGF-β and of IGF-I by immunohistochemistry 
(magnification ×10; all representative data). Scale bars: 100 µm. 
The TGF-β production levels in the TGF-β/IGF-I aggregates were 1.8-, 2.7-, 6.4-, and 8.7-fold 
higher than in the lacZ aggregates on days 2, 7, 14, and 21, respectively (p ≤ 0.050) while they were 
1.5-, 1.4-, 1.5-, and 1.7-fold higher than in the TGF-β/lacZ aggregates at similar time points (p = 0.030, 
p = 0.059, p = 0.070, and p = 0.056, respectively) and 1.7-, 2.3-, 5.5-, and 6.4-fold higher than in the IGF-
I/lacZ aggregates (p ≤ 0.034) (Table 1). They were also higher in the TGF-β/lacZ versus lacZ (1.2-, 1.9-, 
4.2, and 5-fold difference on days 2, 7, 14, and 21, p = 0.148, p = 0.040, p = 0.053, and p = 0.040, 
respectively) and IGF-I/lacZ aggregates at similar time points (1.2-, 1.6-, 3.6-, and 3.7- fold difference, 
p = 0.042, p = 0.015, p = 0.054, and p = 0.059, respectively). No or little difference instead was seen 
between the IGF-I/lacZ and lacZ aggregates at similar time points (p = 0.440, p = 0.087, p = 0.217, and 
p = 0.010, respectively). 
Table 1. Transgene expression in rAAV-transduced hMSC aggregates. 
Assay lacZ TGF-β/lacZ IGF-I/lacZ TGF-β/IGF-I 
TGF-β 
day 2 162 ± 158 196 ± 121 c 166 ± 127 286 ± 169 a,b,c 
day 7 89 ± 93 169 ± 119 a,c 105 ± 93 241 ± 183 a,c 
day 14 19 ± 8 80 ± 73 22 ± 6 121 ± 97 a,c 
day 21 11 ± 3 55 ± 51a 15 ± 4 a 96 ± 80 a,c 
IGF-I 
day 2 52 ± 16 59 ± 22 76 ± 27 a,b 93 ± 53 a 
day 7 52 ± 11 53 ± 14 65 ± 17 a,b 76 ± 29 a,b 
day 14 54 ± 13 52 ± 15 69 ± 15 a,b 73 ± 17 a,b 
day 21 53 ± 16 49 ± 16 67 ± 18 a,b 71 ± 16 a,b 
The levels of TGF-β and IGF-I production are in pg/mL. Data are given as mean ± SD. Statistically 
significant relative to a lacZ, b TGF-β/lacZ, and c IGF-I/lacZ. 
The IGF-I production levels in the TGF-β/IGF-I aggregates were 1.8-, 1.5-, 1.4-, and 1.3-fold 
higher than in the lacZ aggregates on days 2, 7, 14, and 21 (p ≤ 0.030) while they were 1.2-, 1.2-, 1.1-, 
and 1.1-fold higher than in the IGF-I/lacZ aggregates at similar time points (p ≥ 0.120) and 1.6-, 1.4-, 
1.4-, and 1.4-fold higher than in the TGF-β/lacZ aggregates (p = 0.052, p = 0.030, p = 0.014, and p = 0.003, 
respectively) (Table 1). They were also higher in the IGF-I/lacZ versus lacZ (1.5-, 1.3-, 1.3, and 1.3-fold 
difference on days 2, 7, 14, and 21, respectively, p ≤ 0.010) and TGF-β/lacZ aggregates (1.3-, 1.2-, 1.3-, 
and 1.4-fold difference, p ≤ 0.009). No difference was seen between the TGF-β/lacZ and lacZ 
aggregates at similar time points (p ≥ 0.100). 
Figure 2. Detection of transgene (TGF-β, IGF-I) overexpression in rAAV-transduced hMSC aggregates.
Aggregates were co-transduced with rAAV TGF-β/IGF-I, TGF-β/lacZ, IGF-I/lacZ or transduced with
rAAV lacZ as described in Figure 1 and in the Materials and Methods. Samples were processed after 21
days to detect the expression of TGF-β and of IGF-I by immunohistochemistry (magnification ×10; all
representative data). Scale bars: 100 µm.
The TGF-β production levels in the TGF-β/IGF-I aggregates were 1.8-, 2.7-, 6.4-, and 8.7-fold
higher than in the lacZ aggregate o days 2, 7, 14, and 21, resp ctiv ly (p ≤ 0.050) while they were
1.5-, 1.4-, 1.5-, and 1.7-fold higher than in the TGF-β/lacZ aggregates at similar time points (p = 0.030,
p = 0.059, p = 0.070, and p = 0.056, respectively) and 1.7-, 2.3-, 5.5-, nd 6.4-fold higher than in the
IGF-I/lacZ aggregates (p ≤ 0.034) (Table 1). They were also higher i the TGF-β/lacZ versus lacZ (1.2-,
1.9-, 4.2, and 5-fold difference on days 2, 7, 14, and 21, p = 0.148, p = 0.040, p = 0.053, nd p = 0.040,
respectively) an IGF-I/lacZ aggregates at similar time points (1.2-, 1.6-, 3.6-, and 3.7- fol difference,
p = 0.042, p = 0.015, p = 0.054, and p = 0.059, respectively). No or little difference instead was seen
between the IGF-I/lacZ and lacZ aggregates at similar time points (p = 0.440, p = 0.087, p = 0.217, and
p = 0.010, respectively).
Table 1. Transgene expression in rAAV-transduced hMSC aggregates.
Assay lacZ TGF-β/lacZ IGF-I/lacZ TGF-β/IGF-I
TGF-β
day 2 162 ± 158 196 ± 121 c 166 ± 127 286 ± 169 a,b,c
day 7 89 ± 93 169 ± 119 a,c 105 ± 93 241 ± 183 a,c
day 14 19 8 80 ± 73 22 ± 6 121 ± 97 a,c
day 21 11 ± 3 55 ± 51 a 15 ± 4 a 96 ± 80 a,c
IGF-I
day 2 52 ± 16 59 ± 22 76 ± 27 a,b 93 ± 53 a
day 7 52 ± 1 53 ± 14 65 ± 17 a,b 76 ± 29 a,b
day 14 54 ± 3 52 ± 15 69 ± 15 a,b 73 ± 17 a,b
day 21 53 ± 6 49 ± 16 67 ± 18 a,b 71 ± 16 a,b
The levels of TGF-β and IGF-I production are in pg/mL. Data are given as mean ± SD. Statistically significant relative
to a lacZ, b TGF-β/lacZ, and c IGF-I/lacZ.
The IGF-I production levels in the TGF-β/IGF-I aggregates were 1.8-, 1.5-, 1.4-, and 1.3-fold higher
than in the lacZ aggregates on days 2, 7, 14, and 21 (p ≤ 0.030) whil they were 1.2-, 1.2-, 1.1-, an
1.1-fold igher t an in the IGF-I/lacZ aggregates at similar time points (p ≥ 0.120) and 6 , 4 , 4 ,
4 T F-β/lacZ a gregates (p = 0.052, p = 0.030, p = .014, a p = 0.003
respectively) (Table 1). T ey were also higher in the IGF-I/lacZ versus lacZ (1.5-, 1.3-, 1.3, and 1.3-fold
differenc on days 2, 7, 14, and 21, respectively, p ≤ 0.010) and TGF-β/l aggregates (1.3-, 1.2-, 1.3-,
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and 1.4-fold difference, p ≤ 0.009). No difference was seen between the TGF-β/lacZ and lacZ aggregates
at similar time points (p ≥ 0.100).
Overall, these results were corroborated by an evaluation of transgene expression over time
(21 days) on histological stions from aggregates by immunohistochemistry (Figure 2 and Table 2).
Immunoreactivity to TGF-β was more intense in the TGF-β/IGF-I versus lacZ, TGF-β/lacZ, and
IGF-I/lacZ aggregates (3.4-, 1.1-, and 3.1-fold difference, respectively, p ≤ 0.030). It was also higher in
the TGF-β/lacZ versus lacZ and IGF-I/lacZ aggregates (3.2- and 2.9-fold difference, p ≤ 0.020) while
no difference was seen between the IGF-I/lacZ and lacZ aggregates (p = 0.500). Immunoreactivity to
IGF-I was more intense in the TGF-β/IGF-I versus lacZ, TGF-β/lacZ, and IGF-I/lacZ aggregates (3.3-,
2.7-, and 1.1-fold difference, respectively, p ≤ 0.050). It was also higher in the IGF-I/lacZ versus lacZ and
TGF-β/lacZ aggregates (3- and 2.5-fold difference, respectively, p ≤ 0.050) while no difference was seen
between the TGF-β/lacZ and lacZ aggregates (p ≥ 0.050).
Table 2. Histomorphometric analyses in rAAV-transduced hMSC aggregates (day 21).
Assay lacZ TGF-β/lacZ IGF-I/lacZ TGF-β/IGF-I
TGF-β+ cells 26 ± 6 84 ± 6 a,c 29 ± 12 89 ± 4 a,b,c
IGF-I+ cells 27 ± 14 33 ± 8 82 ± 4 a,b 90 ± 5 a,b,c
Cell densities 4817 ± 1348 9061 ± 840 a,c 5628 ± 1116 14,267 ± 1224 a,b,c
Toluidine blue 2.50 ± 0.58 3.75 ± 0.50 a 3.25 ± 0.50 4.00 ± 0.01 a,c
Type-II collagen 1.10 ± 0.32 2.50 ± 0.67 a,c 1.92 ± 0.67 a 3.20 ± 0.42 a,b,c
Type-I collagen 2.60 ± 0.51 1.50 ± 0.52 a 2.00 ± 0.67 a 1.30 ± 0.89 a,c
Type-X collagen 3.40 ± 0.67 2.20 ± 0.83 a,c 2.90 ± 0.67 a 1.30 ± 0.65 a,b,c
Alizarin red 2.90 ± 0.64 1.60 ± 0.74 a,c 2.40 ± 0.52 1.10 ± 0.64 a,b,c
TGF-β+ and IGF-I+ cells are in %. The cell densities are as cells/mm2. Stained (toluidine blue, alizarin red) and
immunostained (type-II, -I, and -X collagen) stions were scored for uniformity and intensity according to a modified
Bern Score grading system [22] as: 0 (no staining), 1 (heterogenous and/or weak staining), 2 (homogeneous and/or
moderate staining), 3 (homogeneous and/or intense staining), and 4 (very intense staining). Data are given as mean
± SD. Statistically significant relative to a lacZ, b TGF-β/lacZ, and c IGF-I/lacZ.
2.2. Biological and Chondrogenic Differentiation Activities of rAAV-Mediated TGF-β and IGF-I
Co-Overexpression in hMSC Aggregates
hMSC aggregates were next transduced with rAAV in order to evaluate the ability of
the TGF-β/IGF-I vector combination to stimulate the proliferative, metabolic, and chondrogenic
differentiation activities of the cells over time (21 days) relative to independent gene application
(TGF-β/lacZ or IGF-I/lacZ) and control (lacZ) treatment.
The levels of cell proliferation measured by the DNA contents in the aggregates were higher in
the TGF-β/IGF-I versus lacZ, TGF-β/lacZ, and IGF-I/lacZ aggregates (1.6-, 1.1-, and 1.4-fold difference,
p = 0.004, p = 0.323, and p = 0.010, respectively) (Table 3). They were also higher in the TGF-β/lacZ
versus lacZ and IGF-I/lacZ aggregates (1.4- and 1.2-fold difference, p = 0.073 and p = 0.094, respectively)
and in the IGF-I/lacZ versus lacZ aggregates (1.2-fold difference, p = 0.010). Overall, these findings
were substantiated by an estimation of the cell densities on H and E-stained histological stions from
aggregates (Figure 3 and Table 2) revealing higher densities in the TGF-β/IGF-I versus lacZ, TGF-β/lacZ,
and IGF-I/lacZ aggregates (3-, 1.6-, and 2.5-fold difference, respectively, p ≤ 0.010), in the TGF-β/lacZ
versus lacZ and IGF-I/lacZ aggregates (1.9- and 1.6-fold difference, respectively, p ≤ 0.010), and in the
IGF-I/lacZ versus lacZ aggregates (1.2-fold difference, p = 0.106).
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Table 3. Biological activities in rAAV-transduced hMSC aggregates (day 21).
Assay lacZ TGF-β/lacZ IGF-I/lacZ TGF-β/IGF-I
DNA 0.029 ± 0.006 0.042 ± 0.018 a 0.034 ± 0.009 a 0.046 ± 0.010 a,c
Proteoglycans 0.3 ± 0.1 0.8 ± 0.7 0.6 ± 0.5 1.0 ± 0.8 a,b,c
The DNA contents are in ng/mg total proteins and the proteoglycan contents in µg/mg total proteins. Data are given
as mean ± SD. Statistically significant relative to a lacZ, b TGF-β/lacZ, and c IGF-I/lacZ.Int. J. Mol. Sci. 2019, 20, x FOR PEER REVIEW 6 of 14 
 
 
Figure 3. Biological and chondrogenic differentiation activities in rAAV-transduced hMSC 
aggregates. Aggregates were co-transduced with rAAV TGF-β/IGF-I, TGF-β/lacZ, IGF-I/lacZ or 
transduced with rAAV lacZ as described in Figures 1 and 2 and in the Materials and Methods. Samples 
were processed after 21 days to evaluate cellularity (H and E staining) and the deposition of matrix 
proteoglycans (toluidine blue staining) and of type-II collagen (immunohistochemistry) 
(magnification x10; all representative data). Scale bars: 100 µm. 
Table 3. Biological activities in rAAV-transduced hMSC aggregates (day 21). 
Assay lacZ TGF-β/lacZ IGF-I/lacZ TGF-β/IGF-I 
DNA 0.029 ± 0.006 0.042 ± 0.018 a 0.034 ± 0.009 a 0.046 ± 0.010 a,c 
Proteoglycans 0.3 ± 0.1 0.8 ± 0.7 0.6 ± 0.5 1.0 ± 0.8 a,b,c 
The DNA contents are in ng/mg total proteins and the proteoglycan contents in µg/mg total proteins. 
Data are given as mean ± SD. Statistically significant relative to a lacZ, b TGF-β/lacZ, and c IGF-I/lacZ. 
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immunostaining were higher in the TGF-β/IGF-I versus lacZ, TGF-β/lacZ, and IGF-I/lacZ aggregates 
(proteoglycans: 3.3-, 1.3-, and 1.7-fold difference, respectively, p ≤ 0.030; toluidine blue: 1.6-, 1.1-, and 
1.2-fold difference, p = 0.007, p = 0.196, and p = 0.030, respectively; type-II collagen: 2.9-, 1.3-, and 1.7-
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TGF-β/lacZ versus lacZ and IGF-I/lacZ aggregates (proteoglycans: 2.7- and 1.3-fold difference 
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collagen: 2.3- and 1.3-fold difference, p ≤ 0.024) and in the IGF-I/lacZ versus lacZ aggregates 
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collagen: 1.7-fold difference, p ≤ 0.001). 
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Differentiation Processes in hMSC Aggregates 
hMSC aggregates were then transduced with rAAV in order to evaluate the capacity of the TGF-
β/IGF-I vector combination to restrain the osteogenic and hypertrophic differentiation activities of 
the cells over time (21 days) relative to independent gene application (TGF-β/lacZ or IGF-I/lacZ) and 
control (lacZ) treatment. 
The osteogenic differentiation activities estimated by monitoring the intensities of type-I 
collagen immunostaining were lower in the TGF-β/IGF-I versus lacZ, TGF-β/lacZ, and IGF-I/lacZ 
aggregates (2-, 1.2-, and 1.5-fold difference, p ≤ 0.001, p = 0.308, and p = 0.048, respectively) (Figure 4 
and Table 2). They were also lower in the TGF-β/lacZ versus lacZ and IGF-I/lacZ aggregates (1.7- and 
Figure 3. Biological and chondrogenic differentiation activities in rAAV-transduced hMSC aggregates.
Aggregates were co-transduced with rAAV TGF-β/IGF-I, TGF-β/lacZ, IGF-I/lacZ or transduced with
rAAV lacZ as described in Figures 1 and 2 and in the Materials and Methods. Samples were processed
after 21 days to evaluate cellularity (H and E staining) and the deposition of matrix proteoglycans
(toluidine blue staining) and of type-II collagen (immunohistochemistry) (magnification ×10; all
representative data). Scale bars: 100 µm.
The chondrogenic differentiation and matrix synthetic activities assessed by monitoring
the proteoglycan contents and the intensities of toluidine blue staining and of type-II collagen
immunostaining were higher in the TGF-β/IGF-I versus lacZ, TGF-β/l , and IGF-I/lacZ aggregates
(proteoglycans: 3.3-, 1.3-, and 1.7-fold difference, respectively, p ≤ 0.030; toluidine blue: 1.6-, 1.1-, and
1.2-fold difference, p = 0.007, p = 0.196, and p = 0.030, respectively; type-II collagen: 2.9-, 1.3-, and 1.7-fold
difference, respectively, p≤ 0.013) (Tables 2 and 3 and Figure 3). They were also higher in the TGF-β/lacZ
versus lacZ and IGF-I/lacZ aggregates (proteoglycans: 2.7- and 1.3-fold difference respectively, p ≥ 0.050;
toluidine blue: 1.5- and 1.2-fold difference, p = 0.008 and p = 0.091; type-II collagen: 2.3- and 1.3-fold
difference, p ≤ 0.024) an in the IGF-I/lacZ versus lacZ aggregates (proteoglycans: 2-fold difference,
p ≥ 0.050; toluidine blue: 1.3-fold difference, p = 0.108; type-II collagen: 1.7-fol difference, p ≤ 0.001).
2.3. Effects of rAAV-Mediated TGF-β and IGF-I Co-Overexpression Upon the Osteogenic and Hypertrophic
Differentiation Processes in hMSC Aggregates
hMSC aggregates were then transduced with rAAV in order to evaluate the capacity of the
F- /IGF-I vector combination to restrain the osteogenic and hypertrophic differentiation activities
of the cells over time (21 days) relative to independent gene application (TGF-β/lacZ or IGF-I/lacZ) and
control (lacZ) treatment.
The osteogenic differentiation activities estimated by monitoring the intensities of type-I collagen
immunostaining were lower in the TGF-β/IGF-I versus lacZ, TGF-β/lacZ, and IGF-I/lacZ aggregates (2-,
1.2-, and 1.5-fold difference, p ≤ 0.001, p = 0.308, and p = 0.048, respectively) (Figure 4 and Table 2). They
were also l wer in the TGF-β/lacZ versus lacZ and IGF-I/lacZ aggregates (1.7- and 1.3-fold differen e,
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p = 0.005 and p = 0.112, respectively) and in the IGF-I/lacZ versus lacZ aggregates (1.3-fold difference,
p = 0.005).
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were processed after 21 days to evaluate the deposition of type-I and -X collagen 
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representative data). Scale bars: 100 µm. 
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Figure 4. Osteogenic and hypertrophic differentiation processes in rAAV-transduced hMSC aggregates.
Aggregates were co-transduced with rAAV TGF-β/IGF-I, TGF-β/lacZ, IGF-I/lacZ or transduced with
rAAV lacZ as described in Figures 1–3 and in the Materials and Methods. Samples were processed
after 21 days to evaluate the deposition of type-I and -X collagen (immunohistochemistry) and matrix
mineralization (alizarin red staining) (magnification ×10; all representative data). Scale bars: 100 µm.
The hypertrophic diff rentiation activities analyzed by evaluating the intensities of type-X
collagen immunostaining and those of alizarin red staining were lower in the TGF-β/IGF-I versus lacZ,
TGF-β/lacZ, and IGF-I/lacZ aggregates (type-X collagen: 2.6-, 1.7-, and 2.2-fold difference, respectively,
p ≤ 0.009; alizarin red: 2.6-, 1.5-, and 2.2-fold difference, respectively, p ≤ 0.020) (Figure 4 and Table 2).
They were also lower in the TGF-β/lacZ versus lacZ and IGF-I/lacZ aggregates (type-X collagen: 1.5- and
1.3-fold difference, p ≤ 0.010; alizarin red: 1.8- and 1.5-fold difference, p ≤ 0.040) and in the IGF-I/lacZ
versus lacZ aggregates (type-X collagen: 1.2-fold difference, p = 0.004; alizarin red: 1.2-fold difference,
p = 0.052).
2 4. Real-Time RT-PCR Analyses in hMSC Aggregates Following rAAV-Mediated TGF-β and IGF-I
Co-Overexpression
Overall, these findings were confirmed by the results of a real-time RT-PCR analysis performed in
hMSC aggregates transduced over time (21 days) with the TGF-β/IGF-I vector combination relative to
independent gene application (TGF-β/lacZ or IGF-I/lacZ) and control (lacZ) treatment (Figure 5).
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Figure 5. Real-time RT-PCR analyses in rAAV-transduced hMSC aggregates. aggregates were
co-transduced with rAAV TGF-β/IGF-I, TGF-β/lacZ, IGF-I/lacZ or transduced with rAAV lacZ as
described in Figures 1–4 and in the Materials and Methods. Samples were processed after 21 days to
monitor the gene expression profiles by real-time RT-PCR as described in the Materials and Methods.
The genes analyzed included the transcription factor SOX9, type-II collagen (COL2A1), aggrecan
(ACAN), type-I collagen (COL1A1), and type-X collagen (COL10A1), with GAPDH serving as a
housekeeping gene and internal control. Threshold cycle (Ct) values were obtained for each target and
GAPDH as a control for normalization, and fold inductions (relative to lacZ aggregates) were measured
using the 2−∆∆Ct method. Statistically significant relative to a lacZ, b TGF-β/lacZ, and c IGF-I/lacZ.
Enhanced chondrogenic differentiation was evidenced by increased SOX9 expression in the
TGF-β/IGF-I versus lacZ, TGF-β/lacZ, and IGF-I/lacZ aggregates (5.3-, 1.9-, and 2.9-fold difference,
p = 0.083, p = 0.059, and p = 0.047, respectively), in the TGF-β/lacZ versus lacZ and IGF-I/lacZ aggregates
(2.7- and 1.5-fold difference, p = 0.146 and p = 0.048, respectively), and in the IGF-I/lacZ versus
lacZ aggregates (1.8-fold difference, p = 0.240). Higher chondrogenic COL2A1 expression was also
noted in the TGF-β/IGF-I versus lacZ, TGF-β/lacZ, and IGF-I/lacZ aggregates (19-, 1.5-, and 2-fold
difference, p = 0.039, p = 0.058, and p = 0.039, respectively), in the TGF-β/lacZ versus lacZ and IGF-I/lacZ
aggregates (12.8- and 1.4-fold difference, p≤ 0.031), and in the IGF-I/lacZ versus lacZ aggregates (9.5-fold
difference, respectively, p = 0.040). Increased chondrogenic ACAN expression was also observed in
the TGF-β/IGF-I versus lacZ, TGF-β/lacZ, and IGF-I/lacZ aggregates (8.6-, 1.9-, and 3.2-fold difference,
p = 0.072, p = 0.056, and p = 0.041, respectively), in the TGF-β/lacZ versus lacZ and IGF-I/lacZ aggregates
(4.4- and 1.6-fold difference, p ≥ 0.102), and in the IGF-I/lacZ versus lacZ aggregates (2.7-fold difference,
p = 0.223).
Reduced osteogenic differentiation was observed by decreased COL1A1 expression in the
TGF-β/IGF-I versus lacZ, TGF-β/lacZ, and IGF-I/lacZ aggregates (30.4-, 8.7-, and 16.9-fold difference,
respectively, p ≤ 0.032), in the TGF-β/lacZ versus lacZ and IGF-I/lacZ aggregates (3.5- and 1.9-fold
difference, p = 0.006 and p = 0.146, respectively), and in the IGF-I/lacZ versus lacZ aggregates (1.8-fold
difference, p = 0.039).
Hypertrophic differentiation (COL10A1 expression) was also restrained in the TGF-β/IGF-I versus
lacZ, TGF-β/lacZ, and IGF-I/lacZ aggregates (3.6-, 2.9-, and 3.4-fold difference, p = 0.017, p = 0.032, and
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p = 0.036, respectively), in the TGF-β/lacZ versus lacZ and IGF-I/lacZ aggregates (1.2-fold difference, p
≤ 0.001 and p = 0.063, respectively), and in the IGF-I/lacZ versus lacZ aggregates (1.1-fold difference,
p = 0.440).
3. Discussion
Direct application of therapeutic gene transfer vectors such as highly effective, clinically
adapted rAAV constructs [13] to articular cartilage lesions is a promising strategy to stimulate
the chondroreparative activities of the bone-marrow-derived MSCs that repopulate the defects
in vivo [11,12,23]. While a number of candidate sequences have been reported for their efficacy
to achieve this goal (TGF-β, FGF-2, IGF-I, SOX9) [14,16–20], none were able to accurately promote
chondrogenic cell differentiation, showing the critical need to explore new lines of research. Based
on the perception that combined treatments may be more beneficial than single approaches [12,21],
we tested the hypothesis that concomitant administration of two highly chondrogenic genes (TGF-β
and IGF-I) stimulates the pro-chondrogenic activities of human MSCs relative to single and control
gene conditions.
Our results first demonstrate that simultaneous expression of TGF-β and IGF-I was significantly
achieved in hMSCs via rAAV over extended periods of time (21 days) and relative to independent
candidate gene delivery and to reporter gene treatment, concordant with previous findings using
rAAV [14,16–20], probably due to the good maintenance of the constructs in such cells without vector
interference [20]. Interestingly, the production levels of each of the candidate genes were always more
elevated in TGF-β/IGF-I co-transduced cells than in those treated with each individual gene, reflecting a
possible interactive regulation of growth factor expression as observed in chondrocytes [24]. The levels
of growth factor production in hMSCs modified with TGF-β/lacZ or by IGF-I/lacZ were in the range of
those reported in our previous studies when using only TGF-β or IGF-I at comparable MOIs (up to
~70–100 pg/mL at MOI = 8) [18,19].
The data next indicate that durable, effective co-overexpression of TGF-β and IGF-I activated the
proliferative, biosynthetic, and chondrogenic activities over time in hMSCs to levels that were more
important than when using independent candidate and reporter gene treatments, as a probable
result of growth factor synergy [25]. This is in good agreement with the properties of these
growth factors [8–10,14,25] and with our previous work using rAAV-hTGF-β and rAAV-hIGF-I
separately [18,19]. Most notably, combined rAAV-mediated TGF-β and IGF-I gene transfer delayed
osteogenic and hypertrophic differentiation in hMSCs relative to independent candidate gene and
reporter gene conditions, possibly due to enhanced levels of anti-hypertrophic SOX9 expression
achieved in TGF-β/IGF-I cells [17,26,27]. Similar trends were also noted upon single TGF-β/lacZ and
IGF-I/lacZ treatments versus lacZ which is in contrast with our previous findings where each vector
(and corresponding growth factor expression) triggered osteogenic and hypertrophic activities in
hMSCs [18,19]. However, in these reports, a higher MOI was applied to the cells (MOI = 20 versus
MOI = 8 in the present study, i.e., a 2.5-fold difference), suggesting that the careful choice of vector
doses will be critical for optimal therapy.
In conclusion, our data uncover the value of combined rAAV-mediated overexpression of TGF-β
and IGF-I to stimulate the chondrogenesis of hMSCs in vitro, as a future, direct therapeutic tool
for administration in sites of cartilage damage. Work is currently ongoing to confirm the findings
in a human osteochondral defect model via implantation of such co-modified hMSCs [28] and in
animal MSCs and in a translational (orthotopic) animal model of focal cartilage defects [29,30].
These evaluations provide a basis for improved cartilage repair upon application of using multiple
candidate rAAV vectors in vivo.
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4. Materials and Methods
4.1. Study Design
High-density aggregate cultures of human bone-marrow-derived MSCs were prepared in defined
chondrogenic medium and then transduced with the different rAAV vectors (total MOI = 8) using the
candidate rAAV-hTGF-β/rAAV-hIGF-I combination (TGF-β/IGF-I; 40 µL + 40 µL vectors/aggregate)
relative to the control conditions of independent vectors rAAV-hTGF-β/rAAV-lacZ (TGF-β/lacZ: 40 µL +
40 µL vectors/aggregate) or rAAV-hIGF-I/rAAV-lacZ (IGF-I/lacZ: 40 µL + 40 µL vectors/aggregate) and
to the lack of therapeutic gene (rAAV-lacZ alone, i.e., lacZ: 80 µL vector/aggregate). A 1:1 ratio of vector
combinations was selected based on our previous work to ensure strict comparison [20]. Aggregates
were kept in defined chondrogenic medium for 21 days and processed to weekly monitor transgene
expression [16,18–20] and to perform biochemical analyses, immunohistochemistry and histology,
and real-time RT-PCR analyses at the time point of 21 days where hMSC chondrodifferentiation fully
occurs [8–10] (Figure 1).
4.2. Reagents
All reagents were from Sigma, Munich (Germany) unless otherwise indicated. The dimethylmethylene
blue dye (DMMB) was from Serva (Heidelberg, Germany). The anti- TGF-β (V) antibody was from
Santa Cruz Biotechnology (Heidelberg, Germany), the anti-IGF-I (AF-291-NA) from R&D Systems
(Wiesbaden, Germany), the anti-type-II collagen (II-II6B3) antibody from NIH Hybridome Bank
(University of Iowa, Ames, IA, USA), the anti-type-I collagen (AF-5610) antibody from Acris Antibodies
(Hiddenhausen, Germany), and the anti-type-X collagen (COL10) antibody from Sigma. Biotinylated
sondary antibodies and ABC reagent were from Vector Laboratories (Alexis Deutschland, Grünberg,
Germany). The TGF-β and IGF-I Quantikine ELISAs were from R&D Systems. The AAVanced
Concentration Reagent was from System Bioscience (Heidelberg, Germany).
4.3. Cell Culture
Bone marrow aspirates were obtained from distal femurs of patients undergoing total knee
arthroplasty (n = 3). All patients included in this study declared in advance informed consent.
All proceedings and methods were executed in compliance with the Helsinki Declaration. The study
was approved by the Ethics Committee of the Saarland Physicians Council. Bone-marrow-derived
hMSCs were first isolated according to standard protocols [16–20,22] by washing and centrifuging the
aspirates (about 15 mL per each patient) in Dulbecco’s modified Eagle’s Medium (DMEM). The pellet
maintained was resuspended in red blood cell lysing buffer and DMEM in equal ratios. The obtained
mixture was washed, pelleted, and resuspended in DMEM containing 10% fetal bovine serum with
100 U/mL penicillin and 100 µL/mL streptomycin. Cells were plated in T75 flasks and kept in an
incubator at 37 ◦C with 5% CO2 overnight. The medium was next removed and substituted by
growth medium containing recombinant FGF-2 (1 ng/mL). Medium was exchanged every 2–3 days.
Proliferating cells were replated when reaching a density of 85%. The hMSCs were used at passage 1–2.
4.4. Plasmids and rAAV Vectors
All rAAV vectors were derived from the AAV-2-based vector plasmid pSSV9 [31,32]. rAAV-lacZ
carries the lacZ gene coding for the Escherichia coli β-galactosidase (β-gal), rAAV-hTGF-β a human
transforming growth factor beta 1 (hTGF-β) complementary DNA (cDNA) sequence, and rAAV-hIGF-I
a human insulin-like growth factor I (hIGF-I) cDNA sequence, all controlled by the cytomegalovirus
immediate-early (CMV-IE) promoter/enhancer [16–20]. rAAV were packaged as conventional (not
self-complementary) vectors using a helper-based system maintaining Adenovirus 5 and pAd8 for
helper functions in the 293 cell line (an adenovirus transformed human embryonic kidney packaging cell
line) [16,17,19,20]. The vector preparations were purified by dialysis using the AAVanced Concentration
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Reagent and titrated by real-time PCR as previously described (approximately 1010 transgene copies/mL
and ratio recombinant functional viral particles-to-recombinant viral particles of about 1/500) [16–20].
4.5. rAAV-Mediated Gene Transfer
hMSCs were pelleted (2 × 105 cells/aggregate) and kept in 150 µL chondrogenic medium (DMEM
high glucose 4.5 g/L, ITS+ Premix, 1 mM pyruvate, ascorbate 2-phosphate 37.5 ng/mL, 10−7 M
dexamethasone, TGF-β3 10 ng/mL) overnight before transduction [16–20]. The hMSC aggregates were
then transduced with the rAAV vector conditions: TGF-β/IGF-I, TGF-β/lacZ, IGF-I/lacZ (40 µL each
vector/aggregate) and lacZ as control condition (80 µL vector/aggregate). rAAV vectors (total MOI = 8)
were directly applied to the aggregates, left at room temperature for one min, filled up with 150 µL
chondrogenic medium and kept at 37 ◦C under 5% CO2 for 24 h. The supernatant was then discarded
and the pellets kept as high-density aggregate cultures in chondrogenic medium for up to 21 days. The
chondrogenic medium was exchanged every 2–3 days.
4.6. Transgene Expression
Transgene expression (TGF-β and IGF-I) was quantitatively estimated by respective ELISAs.
Briefly, aggregates were washed with serum-free medium at the denoted time points and kept in
150 µL DMEM for 24 h. Cell supernatants were then collected and centrifuged to remove debris
and processed according to the manufacturer’s recommendations for evaluation using a GENios
spectrophotometer/fluorometer (Tecan, Crailsheim, Germany) [18–20]. Transgene expression was
also determined by immunohistochemical analyses using paraffin-embedded stions of the constructs
and specific antibodies, biotinylated sondary antibodies, and the ABC detection method using
diaminobenzidine (DAB) as the chromogen [16–20]. Samples were evaluated under light microscopy
(Olympus BX 45, Hamburg, Germany).
4.7. Histological and Immunohistochemical Analyses
Cell aggregates were harvested, fixed in formaldehyde (4%), and dehydrated in graded alcohol [16–20].
Histological and immunohistochemical analyses were performed on paraffin-embedded sections of the
constructs (5 µm). Sections were stained with hematoxylin and eosin (H and E) (cellularity), toluidine
blue (matrix proteoglycans), and alizarin red (matrix mineralization) [16–20]. Immunohistochemical
analyses were performed to detect type-II, -I, and -X collagen expression using specific primary
antibodies, biotinylated secondary antibodies, and the ABC detection method using DAB as the
chromogen [16–20]. Samples were examined under light microscopy (Olympus BX 45).
4.8. Histomorphometric Analyses
The transduction efficiencies (ratio cells positive for TGF-β or IGF-I immunoreactivity to the
total cell number), cell densities (cells/mm2), and the intensities of toluidine blue and alizarin red
staining and those of type-II, -I, and -X collagen immunostaining (ratio tissue surface showing positive
immunoreactivity for particular collagen to the total tissue surface) were measured at three random
sites standardized for their surface or using serial histological or immunohistochemical stions using the
SIS analysisSIS program (Olympus), Adobe photoshop (Adobe Systems, Unterschleissheim, Germany),
and Scion Image (Scion Corporation, Frederick, MD, USA) [16–20]. Stained stions were scored for
uniformity and intensity according to a modified Bern Score grading system [22] as: 0 (no staining), 1
(heterogenous and/or weak staining), 2 (homogeneous and/or moderate staining), 3 (homogeneous
and/or intense staining), and 4 (very intense staining).
4.9. Biochemical Analyses
Aggregates were harvested and digested in papain to monitor the DNA contents by Hoechst 33258
fluorometric assay, the proteoglycan contents by binding to dimethylmethylene blue dye (DMMB), and
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the total cellular protein contents for normalization by using a protein assay (Pierce Thermo Scientific,
Fisher Scientific, Schwerte, Germany) [16–20]. All measurements were performed using a GENios
spectrophotometer/fluorometer (Tecan).
4.10. Real-time RT-PCR Analyses
Total RNA was extracted from aggregates (RNeasy Protect Mini kit, Qiagen, Hilden, Germany)
for reverse transcription (1st Strand cDNA Synthesis kit, avian myeloblastis virus—AMV) (Roche
Applied Science, Mannheim, Germany). cDNA amplification was performed via SYBR Green real-time
RT-PCR (Stratagene, Agilent Technologies, Waldbronn, Germany) maintaining initial incubation (95 ◦C,
10 min), 55 cycles of amplification (denaturation (95 ◦C, 30 s), annealing (55 ◦C, 1 min), extension (72 ◦C,
30 s), denaturation (95 ◦C, 1 min), and final incubation (55 ◦C, 30 s) [16–20]. The following primers
were used: SOX9 (chondrogenic marker) (forward 5′-ACACACAGCTCACTCGACCTTG-3′; reverse
5′-GGGAATTCTGGTTGGTCCTCT-3′), type-II collagen (COL2A1, chondrogenic marker) (forward
5′-GGACTTTTCTCCCCTCTCT-3; reverse 5′-GACCCGAAGGTCTTACAGGA-3′), aggrecan (ACAN,
chondrogenic marker) (forward 5′-GAGATGGAGGGTGAGGTC-3′; reverse 5′-ACGCTGCCTCGGG
CTTC-3′), type-I collagen (COL1A1, osteogenic marker) (forward 5′-ACGTCCTGGTGAAGTTGGTC-3′;
reverse 5′-ACCAGGGAAGCCTCTCTCTC-3′), type-X collagen (COL10A1, hypertrophic marker)
(forward 5′-CCCTCTTGTTAGTGCCAACC-3′; reverse 5′-AGATTCCAGTCCTTGGGTCA-3′), and
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (housekeeping gene and internal control)
(forward 5′-GAAGGTGAAGGTCGGAGTC-3′; reverse 5′-GAAGATGGTGATGGGATTTC-3′) [16–20].
Control conditions included reactions using water and nonreverse-transcribed mRNA. Specificity of
the products was confirmed by melting curve analysis and agarose gel electrophoresis. The threshold
cycle (Ct) value for each gene of interest was measured for each amplified sample using MxPro
QPCR software (Stratagene), and values were normalized to GAPDH expression by using the 2−∆∆Ct
method [16–20].
4.11. Statistical Analysis
Each condition was performed in duplicate in three independent experiments for each patient.
The values obtained are expressed as mean ± standard deviation (SD). A t-test was employed with
p < 0.05 considered statistically significant.
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